NCT06706219View on ClinicalTrials.gov

Efficacy and Safety of SKB264 in Combination With Pembrolizumab in Patients With Initially Unresectable Stage III NSCLC

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

March 31, 2025

Primary Completion Date

March 31, 2028

Study Completion Date

May 31, 2029

Conditions
Non Small Cell Lung Cancer (Stage III)
Interventions
DRUG

Sacituzumab tirumotecan plus pembrolizumab

"Participants meeting the inclusion criteria will receive pembrolizumab 200 mg IV on D1, Q3W + SKB264 4mg/kg IV on D1, D15 and D29，Q2W for 12 weeks as induction therapy.~Subjects who receive radical radiotherapy will undergo 8 cycles of pembrolizumab 200 mg IV on D1, Q3W; For those receiving surgical treatment, pembrolizumab is selected for adjuvant therapy for pCR patients, and SKB264 combination with pembrolizumab is selected non-PCR patients."

Trial Locations (1)

410013

Hunan Provincal Tumor Hospital, Changsha

All Listed Sponsors
lead

Hunan Province Tumor Hospital

OTHER